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Results of Prevention of REStenosis with Tranilast
and its Outcomes (PRESTO) Trial
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P.W. Serruys, MD, PhD; Peter Fitzgerald, MD; David Fischman, MD; Sheldon Goldberg, MD;
Jeffrey A. Brinker, MD; A.M. Zeiher, PhD; Leonard M. Shapiro, MD; James Willerson, MD;
Barry R. Davis, MD, PhD; James J. Ferguson, MD; Jeffrey Popma, MD; Spencer B. King III, MD;
A. Michael Lincoff, MD; James E. Tcheng, MD; Robert Chan, MD;
Jeffrey R. Granett, MD; Marcia Poland, MA
Background—Restenosis after percutaneous coronary intervention (PCI) is a major problem affecting 15% to 30% of
patients after stent placement. No oral agent has shown a beneficial effect on restenosis or on associated major adverse
cardiovascular events. In limited trials, the oral agent tranilast has been shown to decrease the frequency of angiographic
restenosis after PCI.
Methods and Results—In this double-blind, randomized, placebo-controlled trial of tranilast (300 and 450 mg BID for 1
or 3 months), 11 484 patients were enrolled. Enrollment and drug were initiated within 4 hours after successful PCI of
at least 1 vessel. The primary end point was the first occurrence of death, myocardial infarction, or ischemia-driven
target vessel revascularization within 9 months and was 15.8% in the placebo group and 15.5% to 16.1% in the tranilast
groups (P0.77 to 0.81). Myocardial infarction was the only component of major adverse cardiovascular events to show
some evidence of a reduction with tranilast (450 mg BID for 3 months): 1.1% versus 1.8% with placebo (P0.061 for
intent-to-treat population). The primary reason for not completing treatment was 1 hepatic laboratory test abnormality
(11.4% versus 0.2% with placebo, P0.01). In the angiographic substudy composed of 2018 patients, minimal lumen
diameter (MLD) was measured by quantitative coronary angiography. At follow-up, MLD was 1.760.77 mm in the
placebo group, which was not different from MLD in the tranilast groups (1.72 to 1.780.76 to 80 mm, P0.49 to 0.89).
In a subset of these patients (n1107), intravascular ultrasound was performed at follow-up. Plaque volume was not
different between the placebo and tranilast groups (39.3 versus 37.5 to 46.1 mm3, respectively; P0.16 to 0.72).
Conclusions—Tranilast does not improve the quantitative measures of restenosis (angiographic and intravascular
ultrasound) or its clinical sequelae. (Circulation. 2002;106:1243-1250.)
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Prevention of restenosis after percutaneous coronary inter-vention (PCI) remains a challenge despite stent deploy-
ment.1–4 Although the frequency of restenosis has decreased
to 15% to 30% with the widespread use of stent implantation,
this still represents a large population of patients, many of
whom will require a further revascularization procedure for
restenosis. Systemic pharmacological approaches, in general,
have been unsuccessful. Therefore, the results of 2 small
placebo-controlled angiographic trials showing a statistically
and clinically significant reduction in angiographic restenosis
with tranilast5,6 were seen as an opportunity to definitively
assess this agent for the prevention of restenosis.
Tranilast inhibits the release or production of chemical
mediators and cytokines by inflammatory cells and macro-
phages and interferes with the proliferation and migration of
vascular medial smooth muscle cells induced by platelet-
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derived growth factor and transforming growth factor-1.7
The anti-inflammatory effects of tranilast have been demon-
strated by the inhibition of prostaglandin E2, thromboxane B2,
transforming growth factor-1, and interleukin-8 in in vitro
models and by attenuation of the proinflammatory activity of
human monocytes.7 In addition, in various animal models,
tranilast has been shown to reduce neointimal and adventitial
thickening after vascular wall injury.8,9
In 2 angiographic trials, tranilast (600 mg a day for 3
months) decreased the proportion of nonstented patients with
restenosis assessed by quantitative coronary angiography.
Restenosis occurred in 60% of the patients treated with
TABLE 1. Patient Characteristics
Treatment Status and Patient
Characteristics
Placebo
(n2298)
Tranilast BID for 1 mo Tranilast BID for 3 mo
300 mg
(n2306)
450 mg
(n2280)
300 mg
(n2300)
450 mg
(n2300)
US/rest of world, % 43.8/56.2 43.8/56.2 43.9/56.1 43.8/56.2 43.7/56.3
Completed/withdrew treatment, % 85.3/14.7 79.0/21.0 75.6/24.4 76.5/23.5 68.9/31.1
Males 1777 (77.3) 1774 (76.9) 1771 (77.7) 1785 (77.6) 1786 (77.7)
Age, y 60.210.5 60.110.4 60.310.4 60.410.5 60.210.3
Diabetes 553 (24.1) 523 (22.7) 533 (23.4) 546 (23.7) 529 (23.0)
Hypertension 1429 (62.2) 1391 (60.3) 1350 (59.2) 1435 (62.4) 1408 (61.2)
Congestive heart failure 144 (6.3) 145 (6.3) 142 (6.2) 124 (5.4) 141 (6.1)
Statin use 1703 (74.1) 1702 (73.8) 1646 (72.2) 1680 (73.0) 1661 (72.2)
History of angioplasty 705 (30.7) 704 (30.5) 716 (31.4) 738 (32.1) 694 (30.2)
History of CABG 705 (30.7) 704 (30.5) 716 (31.4) 738 (32.1) 694 (30.2)
History of MI 890 (38.7) 904 (39.2) 873 (38.3) 911 (39.6) 875 (38.0)
Recent MI (index PCI reason) 293 (12.7) 305 (13.3) 302 (13.3) 282 (12.2) 300 (13.1)
Unstable angina 649 (28.2) 672 (29.1) 664 (29.1) 652 (28.4) 680 (29.6)
Multivessel disease 406 (17.7) 402 (17.4) 394 (17.3) 431 (18.7) 416 (18.1)
Restenotic vessel 349 (15.2) 385 (16.7) 355 (15.6) 372 (16.2) 362 (15.7)
In-stent restenosis 266 (11.6) 306 (13.3) 285 (12.5) 304 (13.2) 286 (12.4)
No. target vessels 1.20.4 1.20.4 1.20.4 1.20.4 1.20.4
No. target lesions 1.40.7 1.40.7 1.40.7 1.40.7 1.40.7
Target vessel site*
Graft 107 (4.7) 92 (4.0) 119 (5.2) 104 (4.5) 103 (4.5)
LAD 902 (39.3) 900 (39.0) 863 (37.9) 892 (38.8) 932 (40.5)
Right coronary artery 1069 (32.3) 1124 (33.8) 1066 (32.6) 1093 (32.5) 1094 (32.4)
Circumflex 792 (23.9) 738 (22.2) 772 (23.6) 806 (24.0) 747 (22.1)
Left main 29 (0.9) 20 (0.6) 20 (0.6) 19 (0.6) 30 (0.9)
Angioplasty with stent(s) 1935 (84.2) 1920 (83.3) 1917 (84.1) 1921 (83.5) 1944 (84.5)
Lesion diameter 2 mm 548 (99.5) 536 (98.4) 527 (98.7) 554 (99.3) 550 (98.6)
Vessel length, mm
20 48 (8.7) 62 (11.4) 50 (9.4) 60 (10.8) 73 (13.1)
10–20 279 (50.6) 274 (50.3) 266 (49.8) 277 (49.6) 262 (47.0)
Vessel stenosis, % 84.112.0 84.412.0 84.311.8 84.012.4 83.812.5
Lesion morphology
Type A 557 (17.3) 529 (16.3) 522 (16.4) 557 (17.0) 515 (15.8)
Type B1 977 (30.4) 1054 (32.4) 1014 (31.8) 1014 (30.9) 1011 (30.9)
Type B2 1194 (37.2) 1206 (37.1) 1149 (36.0) 1187 (36.2) 1220 (37.3)
Type C 477 (14.9) 452 (13.9) 496 (15.6) 513 (15.7) 514 (15.7)
Total occlusion 202 (6.3) 232 (7.1) 211 (6.6) 222 (6.8) 233 (7.1)
GPIIb/IIIa agents 855 (37.2) 831 (36.0) 827 (36.3) 830 (36.1) 850 (37.0)
Thienopyridines† 2061 (90) 2056 (89) 2053 (90) 2052 (89) 2069 (90)
Values are given as n (%) or meanSD unless otherwise indicated. LAD indicates left anterior descending coronary artery; GP,
glycoprotein.
*Not additive because some patients had 1 target vessel and “other” vessel sites.
†Only 22.8% to 24.5% of patients received ticlopidine; the remainder received clopidogrel.
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placebo compared with 17% of the patients treated with
tranilast in one of the trials (P0.001)5 and in 47% of the
patients treated with placebo compared with 23% of the
patients treated with tranilast in the other trial (P0.001).6 In
a concurrent controlled study, patients who were stented were
compared with those who were treated with both tranilast and
stent10; there was a reduction in angiographic restenosis from
45% to 26% (P0.05).
These trials, although provocative, were limited in scope
and not adequately powered to document statistical differ-
ences in clinical outcomes. Accordingly, the Prevention of
Restenosis With Tranilast and Its Outcomes (PRESTO) trial
was designed to evaluate the effects of tranilast on major
adverse cardiovascular events (MACEs) as well as quantita-
tive angiographic and intravascular ultrasound (IVUS) end
points.
Methods
Study Design
The PRESTO trial has been previously described and was a
double-blind, placebo-controlled, parallel group study of patients
after PCI.11 Successful PCI was defined as at least 1 vessel stenosis
improved to 50% residual stenosis without the occurrence of
MACE before the first dose of study medication. The type of
intervention performed was at investigator discretion, with the
exclusion of experimental procedures, which included intracoronary
radiation at the time of the trial. The protocol and informed consent
were approved by a human research or ethics committee at each
institution and the medical products agencies of the country when
required. Patients were randomized to receive 1 of 5 treatments:
placebo or tranilast at 300 or 450 mg BID for 1 or 3 months. An
angiographic substudy (2000 participants) was also prespecified; in
this substudy, consecutive patients enrolled at selected sites were
required to undergo follow-up angiography at 9 months (or sooner if
clinically warranted). Some of these sites also obtained follow-up
intravascular ultrasound (IVUS) evaluations (for 1000 patients).
When the enrollment in the substudies was complete, these sites then
enrolled the patients into the general protocol. A battery of labora-
tory tests was performed weekly for 4 weeks and then every other
week for 2 months. All blood samples were analyzed by central
laboratories that used the same methodology. Sites were instructed to
use the term “hepatic function abnormal” when the result of at least
1 hepatic laboratory test was 3 times the upper limit of normal
(ULN) and either alkaline phosphatase or total bilirubin reached
ULN. Increases in transaminase levels and hyperbilirubinemia were
defined as being 3 times ULN, and indirect bilirubin was defined as
twice ULN. Abnormal creatinine was defined as an increase of
50% to a level of at least 1.2 mg/dL or a serum creatinine level of
2 mg/dL on 2 consecutive occasions. Anemia was defined as a
hemoglobin of 10 g/dL or a decrease from baseline of 2 g/dL.
The primary efficacy end point was the first occurrence of MACE
within 9 months. Secondary end points were the components of
MACE: all-cause mortality, myocardial infarction (MI), and ische-
mia-driven target vessel revascularization. To avoid the criticism of
angiographic restenosis being ascribed to this end point, the inves-
tigators had to identify and document signs of ischemia before a
repeat angiogram. MI was defined as having at least 2 of the
following: (1) characteristic ischemic pain lasting 20 minutes, (2)
creatine kinase 3 times ULN and creatine kinase-MB 2 times
ULN, or (3) development of a new 40-ms Q waves in at least 2
adjacent ECG leads or new dominant R waves in V1. Ischemia-
driven revascularization was defined as intervention for chest pain or
a positive test for ischemia (exercise stress test, stress echocardio-
gram, 24-hour Holter monitor, resting ECG evidence of ST-segment
depression or elevation in 1 lead, or radionuclide study showing a
reversible defect). An independent clinical event committee con-
firmed any MACE.11 Other major secondary variables of interest
included minimal lumen diameter (MLD) by quantitative coronary
angiography and plaque volume by IVUS. As previously de-
scribed,11 the angiograms and IVUS films were read by 2 laborato-
ries each. Both angiography laboratories used the Cardiovascular
Measurement System (Medis Medical Imaging Systems) for quan-
titative measurements. Restenosis was defined as 50% stenosis in
a treated segment at follow-up. To compare the restenosis rates for
tranilast with those previously reported by Tamai and colleagues,5,6
restenosis was also analyzed as 50% loss of acute gain.
Power Calculations and Statistical Analysis
An expected incidence of 18% in the primary MACE end point based
on prior published trials, including the results of the Evaluation of
Platelet IIB/IIIA Inhibitor for STENTing (EPISTENT) trial,12 was
used for calculations of sample size. The overall type I error was
selected so that the statistical evidence of efficacy would be
equivalent to that provided by 2 positive trials at a level of
significance of 0.05 and also to control for multiple group compar-
isons. Randomizing 2300 patients to each group provided 90%
power to detect a reduction from 18% to 12.6% (30% relative
reduction) among any or all tranilast groups by using 2-sided
log-rank tests with an overall  value of 0.00125.13,14
An intent-to-treat population was analyzed for the primary anal-
ysis, which was defined as all randomized patients who received at
least 1 dose of study medication. The frequency of the first
occurrence of MACE was analyzed by using a modified Bonferroni
procedure.15 Significance levels for pairwise comparisons with
placebo were derived from log-rank tests, stratifying for center. Cox
proportional hazards models were used to calculate hazard ratios
(tranilast/placebo) with associated 95% CIs. In the model, the
independent variables were center and treatment. Kaplan-Meier
curves were calculated for MACE as well.
In the angiographic substudy, the minimum clinically relevant
treatment difference was assumed to be 0.2 mm (SD of 0.7 mm)
between treatment groups at follow-up.4 Therefore, 400 patients per
arm were required to detect this reduction with 93% power at an 
value of 0.05. To ensure that 2000 patients had follow-up angio-
grams, the protocol required that 2666 patients be enrolled in this
substudy. Dichotomous restenosis rates were also analyzed.
In the IVUS substudy, the minimum treatment difference consid-
ered clinically relevant was assumed to be a 20% difference between
treatment groups at follow-up. Based on a normal distribution curve
in 100 patients at the Stanford Core Laboratory, the mean plaque
TABLE 2. Results of Primary Composite End Point of MACE
Primary Efficacy
End Point
Placebo
(n2298)
Tranilast BID for 1 mo Tranilast BID for 3 mo
300 mg
(n2306)
450 mg
(n2280)
300 mg
(n2300)
450 mg
(n2300)
At least 1 MACE,* n (%) 358 (15.7) 352 (15.4) 351 (15.5) 363 (16.0) 364 (16.0)
Hazard ratio (95% CI) 0.98 (0.85–1.14) 0.98 (0.84–1.13) 1.02 (0.88–1.18) 1.02 (0.88–1.18)
P vs placebo† 0.81 0.77 0.81 0.77
*Risks are Kaplan-Meier product-limit estimates.
†Derived from log-rank test.
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volume was expected to be 41.91 mm3 (SD of 17.67 mm3). With
this assumption, 140 stented patients per group were required to
detect a 20% reduction with 80% power at an  value of 0.05.
Results
Patient Characteristics
Four hundred thirty-two centers (224 in the United States,
166 in Western Europe, 27 in Canada, 7 in Eastern Europe,
and 8 in Australia/South Africa) enrolled 11 484 patients
between April 1999 and July 2000, with the last patient visit
on April 18, 2001. The groups were well matched and
consistent with the expected moderate risk of restenosis based
on the proportion of patients with factors known to be
associated with restenosis (Table 1). The mean number of
target vessels was 1.2, and the mean number of target lesions
was 1.4.
The angiographic subset (n2018) was not clinically
different from the population as a whole or from a random
sample of patients not in the angiographic subset: 77% were
male, 40% had a previous MI, 24% were diabetic, and 13%
underwent PCI after an MI. The mean numbers of target
vessels and lesions were identical to those of the general
population: 15% had restenotic lesions, 12% had in-stent
restenosis, and 83% received a stent. The IVUS population
(n1107) was similar to the PRESTO population and similar
to a random sample of patients not in the angiography subset
(data not shown). However, there was some evidence that the
patients in the IVUS subset had larger vessel diameters (mean
stent diameter of 3.4 versus 3.2 mm for the angiographic
subset). A total of 1180 lesions were evaluated by IVUS; only
73 (6%) were in nonstented vessels.
MACE During 9 Months
The frequency of the first occurrence of MACE in the placebo
group was slightly lower than predicted (15.7%). The MACE
rate was virtually identical among all 4 tranilast groups, and
there was no decrease from placebo (Table 2). MACE rates
were driven by ischemia-induced target vessel revasculariza-
tion; the frequency of death and MIs were low, occurring in
only 1% to 1.8% of the population (Figure 1). Extensive
subgroup analyses were performed. The relative risk of
MACE by subgroups (Figures 2 and 3) revealed no differ-
ences between tranilast and placebo in any subgroup. As
expected, mortality was low in this study population. No
trends in favor of any dose of tranilast were observed for
death or ischemia-driven target vessel revascularization. To
test whether early withdrawals were responsible for the lack
of effect, an analysis was performed in patients who com-
pleted treatment with no treatment effect observed.
A possible trend in favor of tranilast (450 mg BID)
compared with placebo was observed in the frequency of
follow-up MIs (hazard ratio 0.62, 95% CI 0.38 to 1.03;
P0.061). To ascertain the strength of this trend, an analysis
of patients who completed at least 84 days of treatment was
undertaken; the hazard (tranilast/placebo) ratio for follow-up
Figure 1. Percentage of patients with each component of
MACE.
Figure 2. Subgroup analyses of MACE outcome differences
between placebo and tranilast.
Figure 3. Subgroup analyses of MACE outcome differences
between placebo and tranilast.
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MI decreased to 0.44 (95% CI 0.23 to 0.85), and the
significance was P0.012.
Angiographic and IVUS Results
Informed consent was given by 2682 patients for the angio-
graphic substudy, and follow-up was terminated when 2018
patient follow-up films had been submitted to the core
laboratories (75%). At the time of the index procedure, the
mean target vessel reference diameters and MLD as well as
the percent stenosis and residual stenosis were similar across
treatment groups. There were no statistically or clinically
significant differences in the angiographic variables immedi-
ately after the index PCI or at follow-up (Table 3). These data
are represented in Figure 4 by the cumulative curves of MLD
in the placebo group and the highest dose/duration of the
tranilast group.
Angiographic restenosis by patient and lesion (Table 3)
showed no significant differences between tranilast and
placebo (P0.46 to 1.00). However, there was a significant
(P0.001) correlation between the frequency of restenosis
across treatment groups and the occurrence of MACE (Table
4). This was again related to target vessel revascularization.
Patients who had no evidence of restenosis with 50%
stenoses by angiography were significantly less likely to have
a MACE.
There were no clinically or statistically significant differ-
ences among the treatment groups in any of the intracoronary
ultrasound measurements (Table 5).
Adverse Events
The most frequently reported adverse experiences were lab-
oratory test abnormalities consisting of hyperbilirubinemia,
elevations in hepatic (transaminase) enzymes, and hepatic
function abnormal (Table 6). In addition, there were increases
in serum creatinine and decreases in hemoglobin reported as
anemia. The majority of the increases in serum creatinine
Figure 4. Cumulative distribution curves of MLD for highest
dose/duration of tranilast (450 mg BID for 3-month group) com-
pared with placebo.
TABLE 4. Correction Between Angiographic Restenosis
and MACE
Association With
Restenosis
Angiographic Restenosis
50% Stenosis
Total, n (%)Yes, n (%) No, n (%)
MACE
Yes 313 (46)* 73 (5) 386 (19)
No 371 (54) 1261 (95)* 1632 (81)
Totals 684 (100) 1334 (100) 2018 (100)
*Positive predictive value313/6840.458 (0.019); negative predictive
value1261/13340.945 (0.006); P value from 2 test for association
(P0.001).
TABLE 3. Quantitative Angiographic Analysis
Angiographic End Points by Patient
Placebo
(n420)
Tranilast BID for 1 mo Tranilast BID for 3 mo
300 mg
(n407)
450 mg
(n389)
300 mg
(n415)
450 mg
(n387)
Baseline
Reference diameter, mm 2.900.51 2.920.54 2.940.52 2.930.51 2.920.57
MLD, mm 0.810.43 0.860.48 0.790.47 0.850.45 0.830.42
Stenosis, % 72.114.2 71.114.6 73.014.9 70.814.9 71.613.2
MLD immediately after PCI, mm 2.700.56 2.690.60 2.720.58 2.740.56 2.740.62
Acute gain in MLD, mm 1.890.64 1.830.63 1.940.67 1.890.65 1.910.64
Residual stenosis, % 10.011.9 10.513.1 9.512.4 9.312.4 9.711.6
MLD at follow-up,* mm 1.760.77 1.720.80 1.770.76 1.750.79 1.780.77
Change in MLD from immediately after
PCI (late loss), mm
0.960.76 0.9720.75 0.9720.79 1.000.79 0.970.76
% Stenosis at follow-up 39.523.8 40.524.0 38.823.1 39.723.4 38.722.9
Ratio of late loss/acute gain 0.520.45 0.570.50 0.490.48 0.540.44 0.520.41
Restenosis rate: 50% stenosis
Lesions, % 30.1 29.8 28.5 29.8 29.0
Patients,† % 33.3 35.1 33.4 35.2 32.3
Values are meanSD unless specified otherwise.
*In patients with multiple lesions/vessels, MLD was averaged.
†Restenosis of any lesion.
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were 50% increases to values 1.2 mg/dL. Less than 1% of
the patients in all treatment groups had a serum creatinine 2
mg/dL at the termination of double-blind treatment. The
hepatic and renal laboratory abnormalities as well as anemia
were related to both the dose of tranilast and the duration of
tranilast treatment (ie, the higher the dose and the longer the
duration of treatment, the higher was the frequency). These
laboratory abnormalities, when followed, were all reversible
with discontinuation of the study medication.
Discussion
Tranilast was not significantly more effective than placebo at
total daily doses of 600 and 900 mg a day administered for 1
or 3 months in reducing the frequency of MACE or angio-
graphic restenosis in a broad group of patients undergoing
PCI. In addition, it did not decrease neointimal hyperplasia as
measured by IVUS. The incidence of MACE in the placebo
group was 15.7%, and the incidence of MACE in the tranilast
groups ranged from 15.5% to 15.0%. In the angiographic
TABLE 5. IVUS Analysis at Follow-Up of Patients Who Had at Least 1 Stented Vessel
IVUS End Points at Follow-Up
Placebo
(n224)
Tranilast BID for 1 mo Tranilast BID for 3 mo
300 mg
(n211)
450 mg
(n222)
300 mg
(n230)
450 mg
(n220)
Plaque volume, mm3
MeanSD 39.326.2 37.526.9 45.332.3 45.547.1 46.136.7
P vs placebo    0.72 0.22 0.20 0.16
Mean luminal area, mm2
MeanSD 5.51.94 5.92.27 5.22.19 5.72.45 5.52.63
P vs placebo    0.19 0.42 0.42 0.93
Plaque area, mm2
MeanSD 2.72.61 2.42.45 2.72.13 2.31.56 2.72.23
P vs placebo    0.32 0.93 0.16 0.97
Mean total vessel area, mm2
MeanSD 5.73.0 6.93.0 7.43.2 6.23.5 4.82.8
P vs placebo    0.33 0.17 0.71 0.50
TABLE 6. Most Frequently (>2%) Reported Adverse Experiences Considered at
Least Possibly Related to Tranilast
WHO Body System and Preferred
Term Placebo
Tranilast BID for 1
mo
Tranilast BID for 3
mo
300 mg 450 mg 300 mg 450 mg
Gastrointestinal
Abdominal pain, % 1 1 1 2 2
Nausea, % 1 1 2 1 2
Liver/biliary system
Hyperbilirubinemia, % 1 2 8 4 12
Hepatic function abnormal, % 1 5 7 7 9
Hepatic enzymes increased, % 1 3 4 5 6
SGPT increased, % 1 2 3 3 3
Metabolic
Creatinine increased, % 1 2 3 3 5
Red blood cells
Anemia, % 1 1 2 1 4
Skin and appendages
Rash, % 1 1 1 1 2
Urinary system
Dysuria, % 1 2 2 2 3
WHO indicates World Health Organization; SGPT, serum glutamic pyruvic transaminase. Events
within body system are not additive because some patients are counted in multiple preferred terms
listed under body system.
*Procedural injury includes hematoma, pain, oozing, pseudoaneurysm, and bruising at catheter
insertion sight.
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substudy, a 50% loss of acute gain was found in 50% of the
patients treated with placebo and in 49% to 52% of the
patients treated with tranilast. These findings are in contrast
to the statistically significant and clinically relevant resteno-
sis rates associated with tranilast treatment observed previ-
ously in the Tranilast Restenosis Following Angioplasty Trial
(TREAT trial) (Figure 5).5,6 In the TREAT 1 trial,5 MLD at
follow-up was 1.54 mm in the placebo group and 1.82 mm in
the tranilast (600 mg) group (P0.001). The MLD in the
PRESTO trial at follow-up in the tranilast group was
1.76 mm, which was not different from that observed with
tranilast (600 mg for 3 months) in the TREAT trial. What is
different is that the MLD in the placebo group in the PRESTO
trial was larger (at 1.75 mm). Immediately after PCI, the
MLD in the TREAT 1 trial was significantly larger in the
tranilast group than in the placebo group (2.27 versus
1.54 mm, respectively; P0.029). MLD was not reported for
the TREAT 2 trial.6
In the TREAT trials, restenosis defined as a 50% loss of
acute gain was reported for 17% and 23% (Figure 5) of the
patients. TREAT 1 reported that 43.1% of the placebo-treated
patients had a 50% stenosis compared with 20.3% of the
patients treated with tranilast (600 mg a day). Compared with
the PRESTO trial, these trials were small and generally
included patients at lower risk of restenosis. In the TREAT 1
trial, 85 or 86 patients per treatment group were randomized,
and in the second TREAT trial, 114 to 118 were randomized.
These trials excluded lesions in the side branches, left main
disease, grafts, lesions 20 mm, lesions responsible for MIs
within 2 weeks of study entry, patients with no thrombus or
dissection, and Thrombolysis in Myocardial Infarction
(TIMI) grades 1. All of these exclusion criteria were
allowed in the PRESTO trial. In the TREAT trials, patients
who did not complete treatment were eliminated from anal-
ysis; 28% of the patients were excluded. The PRESTO
analysis was an intent-to-treat whereby all patients who
received at least 1 dose of medication were included.
Two trials reported the frequency of MACE during a
1-year follow-up. In the TREAT 1 study,5 there were no MIs
or deaths. In the second, a concurrent control study in patients
who underwent directional coronary atherectomy (DCA),16
the frequency of MI was 0.7% in the DCA-only group
compared with 0% in the DCA plus tranilast (600 mg a day
for 3 months) group. These frequencies are based on a
denominator of patients who completed the 3 months of
treatment and were valid for efficacy analyses. To make like
comparisons, the frequency of MI in the placebo group for
those patients who completed 84 days in the PRESTO trial
was calculated, and among those patients, a significant
reduction in the frequency of MI was seen in the 3-month
tranilast (450 mg BID) group compared with the placebo
group (0.4% versus 1.6%, respectively; P0.002). The ben-
eficial effect of tranilast on the frequency of MIs may, in part,
be due to its attenuation of the proinflammatory activity of
human monocytes/macrophages.7 Alternately, the reduction
in the frequency of MIs may be the result of multiple analyses
on multiple end points and, therefore, may be spurious.
Although there were no differences between the tranilast
and placebo groups in the primary efficacy end point of
MACE and in the secondary efficacy end point of angio-
graphic restenosis, there were both dose-related and duration-
related laboratory test abnormalities reported as adverse
experiences. These abnormalities were reversible on the
cessation of tranilast treatment. The adverse experience
profile in the present study was similar to that reported by
Tamai and colleagues.5,6 Had the study met the primary
efficacy criteria, it was believed that the benefit of reducing
the incidence of MACE would outweigh the risk. However,
even if the benefit observed in the reducing subsequent MIs
proved to be reproducible, this advantage would probably still
not outweigh the risk of developing liver laboratory test
abnormalities.
The lack of efficacy demonstrated by tranilast in the
PRESTO study was unexpected and clearly failed to confirm
earlier reports.5,6,10,16 This underscores and emphasizes the
critical importance of subjecting the findings of studies
limited in scope and sample size (even when “statistically
significant”) to robust, large-scale, definitive trials adequately
powered to avoid type I errors.
Prevention of restenosis has been very difficult but
remains very important because of recurrent symptoms and
the need for subsequent procedures when restenosis oc-
curs. Multiple device and medication strategies have been
tested; typically, small experimental or pilot human studies
form the rationale for larger more definitive studies. These
larger definitive studies are aimed at overcoming the
limitations of small studies. The PRESTO trial followed
the same time course of other investigations, from small
pilot studies to a definitive large study, which in this case
was negative. Ever since the design and performance of the
PRESTO trial, new data have accumulated that appear
encouraging. Information continues to accumulate on the
efficacy of vascular brachytherapy for treatment of in-stent
restenosis (although not for prevention of initial resteno-
sis). Even more exciting are the initial data on drug-coated
stents, which dramatically prevent restenosis.
In conclusion, in this multicenter, large, randomized clin-
ical trial, administration of tranilast in 2 different doses for 2
different durations was associated with no improvement in
either angiographic or clinical restenosis compared with
administration of placebo alone.
Figure 5. Restenosis defined as 50% loss of acute gain in
PRESTO vs TREAT 1 and TREAT 2 trials.
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Appendix
Institutions and Investigators
Institutions and investigators who enrolled at least 45 patients in the
PRESTO trial can be found in the online version of the present study,
available at http://circ.ahajournals.org.
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